Payment overview · 2025
General Payments
$1,282.26
60 reported records · 14 companies
Healthcare provider profile · identity verified
Imad Alazem, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · DEARBORN, MI · NPI 1265402630
Verified facts
What the public records show
CMS Open Payments records show Imad Alazem, M.D. received $1,282.26 in general payments during 2025 across 60 reported records.
ABBVIE INC. accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Orencia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORENCIA as an associated drug or biological on 10404 records involving 2463 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Orencia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $362.47 | 28.3% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $212.44 | 16.6% | 14 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $115.39 | 9.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $96.37 | 7.5% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $87.91 | 6.9% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $82.24 | 6.4% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $78.00 | 6.1% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $60.77 | 4.7% | 3 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $45.82 | 3.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.39 | 3.5% | 2 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $24.64 | 1.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.25 | 1.9% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $24.24 | 1.9% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $22.33 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,204.27 | 59 |
| Education | $77.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $187.76 | 7 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $174.71 | 6 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $97.51 | 2 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $96.37 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $86.69 | 7 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $82.24 | 5 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $78.00 | 4 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $70.45 | 4 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $60.77 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $55.39 | 3 | 2025 |
Source payment records
|
|||||
| Kineret Normalized: kineret |
Drug | SOBI, INC | $45.82 | 2 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $45.39 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $36.90 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $24.24 | 2 | 2025 |
Source payment records
|
|||||
| RENFLEXIS Normalized: renflexis |
Drug | Organon LLC | $24.24 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| REMICADE Normalized: remicade |
Biological | Janssen Biotech, Inc. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| ILARIS Normalized: ilaris |
Drug | Novartis Pharmaceuticals Corporation | $17.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ORENCIA orencia |
2025 | Orencia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ORENCIA open payments reported associated product |
CMS Open Payments — General Payments 10404 supporting records · 2463 recipient NPIs · example record 1184378623 |
Orencia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Methotrexate | Methotrexate Sodium | 578 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 280 | 78 |
| Meloxicam | Meloxicam | 237 | 75 |
| Prednisone | Prednisone | 202 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 194 | 34 |
| Baclofen | Baclofen | 174 | 60 |
| Tramadol Hcl | Tramadol Hcl | 169 | 32 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 167 | 41 |
| Losartan Potassium | Losartan Potassium | 158 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 139 | 41 |
| Trazodone Hcl | Trazodone Hcl | 113 | 32 |
| Celecoxib | Celecoxib | 111 | 28 |
| Gabapentin | Gabapentin | 111 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 41 |
| Lisinopril | Lisinopril | 98 | 34 |
| Simvastatin | Simvastatin | 93 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 92 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 91 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 31 |
| Metformin Hcl | Metformin Hcl | 91 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 30 |
| Omeprazole | Omeprazole | 81 | 30 |
| Alprazolam | Alprazolam | 78 | 17 |
| Folic Acid | Folic Acid | 74 | 20 |
| Sertraline Hcl | Sertraline Hcl | 70 | 18 |
| Allopurinol | Allopurinol | 69 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 18 |
| Sulfasalazine | Sulfasalazine | 63 | 17 |
| Carvedilol | Carvedilol | 59 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 20 |
| Leflunomide | Leflunomide | 55 | 20 |
| Potassium Chloride | Potassium Chloride | 55 | 26 |
| Furosemide | Furosemide | 49 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 44 | 11 |
| Ibuprofen | Ibuprofen | 41 | 16 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Cephalexin | Cephalexin | 36 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 27 |
| Glimepiride | Glimepiride | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 29 | 13 |
| Colchicine | Colchicine | 28 | 11 |
| Eliquis | Apixaban | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Famotidine | Famotidine | 26 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 11 |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 18 |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 12 |
| Spironolactone | Spironolactone | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Orencia | Abatacept/Maltose | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,282.26 · 60 records | ABBVIE INC. | BENLYSTA, Bimzelx, COSENTYX, EVENITY, HADLIMA, ILARIS, KRYSTEXXA, Kineret, Leqembi, ORENCIA, OTEZLA, Ocrevus Zunovo, REMICADE, RENFLEXIS, RINVOQ, SAPHNELO, SIMPONI ARIA, SKYRIZI, TAVNEOS, TREMFYA, XELJANZ | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Orencia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error